EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone

Yuki Otsuka iD, Yoshiaki Soejima iD, Yasuhiro Nakano iD, Atsuhito Suyama, Ryosuke Takase, Kohei Oguni, Yohei Masuda iD, Daisuke Omura, Yasue Sakurada iD, Yui Matsuda, Toru Hasegawa, Hiroyuki Honda iD und 3 weitere

International Journal of Molecular Sciences · 14.01.2026 · 27 (2) · 832

DOI: 10.3390/ijms27020832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.01.2026. Verfasst von Yuki Otsuka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Ok…. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, COVID-19, Hypothalamus, Hypothalamic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ofuji Endocrine Medical Award, Growth Science Foundation, Kobayashi-Magobei Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long COVID (LC) may involve endocrine dysfunction; however, the underlying mechanism remains unclear. To examine hypothalamic–pituitary responses in patients with LC, we conducted a single-center retrospective study of patients with refractory LC referred to our University Hospital who underwent anterior pituitary stimulation tests. Between February 2021 and November 2025, 1251 patients with long COVID were evaluated, of whom 207 (19%) had relatively low random ACTH or cortisol levels. Ultimately, 16 underwent anterior pituitary stimulation tests and were included. All tests were performed in an inpatient setting without exogenous steroids. Fifteen patients (six women, mean age 35.6 years) underwent corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and gonadotropin-releasing hormone (GnRH) tests. All patients had mild acute COVID-19, eight had ≥2 vaccinations, and the mean interval from infection was 343 days. Frequent symptoms included fatigue (100%), insomnia (66.7%), headache (60.0%), anorexia/nausea (40.0%), and brain fog (40.0%). Mean early-morning cortisol and 24 h urinary free cortisol were 7.5 μg/dL and 41.0 μg/day, respectively. MRI showed an empty sella in one case. Peak hormonal responses were preserved (ΔACTH 247%, ΔTSH 918%, ΔPRL 820%, ΔFSH 187%, ΔLH 1150%); however, peaks were delayed beyond 60 min in ACTH (13%), LH (33%), and FSH (87%). Notably, significantly delayed elevations remained at 120 min in the responses of TSH (4.1-fold), PRL (1.8-fold), LH (9.3-fold), and FSH (2.8-fold), suggesting possible hypothalamic involvement, particularly in the gonadotropin responses. Additionally, serum IGF-I was lowered (−0.70 SD), while GH response (mean peak 35.5 ng/mL) was preserved by growth hormone-releasing peptide (GHRP)-2 stimulation. Low-dose hydrocortisone and testosterone were initiated for three patients. Although direct viral effects and secondary suppression have been proposed, our findings may suggest that, at least in part, the observed response characteristics are consistent with functional secondary hypothalamic dysfunction rather than irreversible primary injury. These findings highlight the need for objective endocrine evaluation before initiating hormone replacements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gonadotropin-Releasing HormoneCOVID-19HypothalamusHypothalamic DiseasesHumansFemaleAdultPost-Acute COVID-19 SyndromeRetrospective StudiesMaleHydrocortisoneMiddle AgedCorticotropin-Releasing HormoneAdrenocorticotropic HormoneSARS-CoV-2Hypothalamo-Hypophyseal SystemHypothalamic-Pituitary-Gonadal Axis

Stichwörter der Autor:innen

COVID-19gonadotropingonadotropin-releasing hormone (GnRH)hypothalamuslong COVID

Substanzen

Gonadotropin-Releasing HormoneHydrocortisoneCorticotropin-Releasing HormoneAdrenocorticotropic Hormone

Autor:innen und Institutionen

  • Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.

ORCID-Profile: Yuki Otsuka, Yoshiaki Soejima, Yasuhiro Nakano, Yohei Masuda, Yasue Sakurada, Hiroyuki Honda, Kazuki Tokumasu, Fumio Otsuka

Förderung

  • Ofuji Endocrine Medical Award
  • Growth Science Foundation
  • Kobayashi-Magobei Foundation
  • Kobayashi Magobe Memorial Medical Foundation

Zitieren

APA

Otsuka, Y., Soejima, Y., Nakano, Y., Suyama, A., Takase, R., Oguni, K., Masuda, Y., Omura, D., Sakurada, Y., Matsuda, Y., Hasegawa, T., Honda, H., Tokumasu, K., Ueda, K., & Otsuka, F. (2026). Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone. International Journal of Molecular Sciences, 27(2), 832. https://doi.org/10.3390/ijms27020832

Vancouver

Otsuka Y, Soejima Y, Nakano Y, Suyama A, Takase R, Oguni K, et al. Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone. International Journal of Molecular Sciences. 2026;27(2):832. doi:10.3390/ijms27020832

BibTeX
@article{Otsuka2026,
  author = {Otsuka, Yuki and Soejima, Yoshiaki and Nakano, Yasuhiro and Suyama, Atsuhito and Takase, Ryosuke and Oguni, Kohei and Masuda, Yohei and Omura, Daisuke and Sakurada, Yasue and Matsuda, Yui and Hasegawa, Toru and Honda, Hiroyuki and Tokumasu, Kazuki and Ueda, Keigo and Otsuka, Fumio},
  title = {Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {832},
  doi = {10.3390/ijms27020832}
}
Kostenlos starten →